Psoriasis is one of the most common chronic inflammatory skin
disorders worldwide with a significant number of patients suffering from
moderate to severe disease and requiring systemic therapy. Over the past
two decades, better knowledge of disease pathophysiology has translated
into treatment advances for both primary disease and its associated comorbidities.
However, it is important to review the use of biologic or targeted
therapy in a clinical setting in order to understand how to optimize therapeutic
results and recognize any unmet needs in this patient subpopulation.
We conducted a retrospective study on a cohort of patients diagnosed with
psoriasis that had received at least one dose of biologic or targeted therapy
for the treatment of psoriasis at the Rijeka Clinical Hospital Center. By
documenting treatment trends and specific patient characteristics, we will
be able to address any unmet needs in this patient population and provide
individualized care strategies
